Antibe Therapeutics (ATBPF) Stock Price, News & Analysis

Company Overview

Antibe Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapies for pain and inflammation. The company’s proprietary platform harnesses the anti-inflammatory properties of hydrogen sulfide (H₂S) release to improve the safety profile of traditional non-steroidal anti-inflammatory drugs (NSAIDs). By coupling H₂S-releasing moieties to existing molecules, Antibe aims to maintain or enhance efficacy while reducing gastrointestinal and cardiovascular side effects commonly associated with long-term NSAID use.

The company’s lead product candidate, otenaproxesul (ATB-346), is an H₂S-releasing derivative of naproxen that has demonstrated promising safety and efficacy in Phase II clinical trials for osteoarthritis-related pain. Antibe is also advancing other pipeline candidates, including ATB-352 (an H₂S-releasing derivative of ketoprofen) and novel small-molecule anti-inflammatory compounds targeting acute pain conditions. These programs are designed to address large, underserved markets such as post-operative pain, musculoskeletal disorders and chronic inflammatory diseases.

Headquartered in Toronto, Ontario, Antibe Therapeutics was founded in 2009 as a spin-out of research conducted at the Lunenfeld-Tanenbaum Research Institute at Sinai Health System. The company operates research and development facilities in Canada and collaborates with clinical sites across North America and Europe to advance its pipeline. Antibe’s leadership team is led by Chief Executive Officer Bruce Colwill, who brings extensive experience in pharmaceutical development, and Chief Scientific Officer Matthew Giuffrida, a recognized expert in gasotransmitter biology.

Key Stats

• Today's Range: $0.22 to $0.22
• 50-Day Range: $0.22 to $0.22
• 52-Week Range: $0.11 to $0.89
• Volume: N/A
• Average Volume: 27,352 shs
• Market Capitalization: $11.42 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ATBPF Stock Analysis - Frequently Asked Questions

How have ATBPF shares performed this year?

Antibe Therapeutics' stock was trading at $0.2156 at the beginning of 2025. Since then, ATBPF stock has increased by 0.0% and is now trading at $0.2156.

How were Antibe Therapeutics' earnings last quarter?

Antibe Therapeutics Inc. (OTCMKTS:ATBPF) posted its quarterly earnings results on Monday, November, 13th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.02.

How do I buy shares of Antibe Therapeutics?

Shares of ATBPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 11/13/2023
• Today: 10/18/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:ATBPF
• CIK: N/A
• Web: www.antibethera.com
• Phone: (416) 922-3460
• Fax: N/A
• Employees: 11
• Year Founded: 2009

Profitability

• EPS (Trailing Twelve Months): ($0.25)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$14.73 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -56.48%
• Return on Assets: -29.07%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.06
• Quick Ratio: 10.06

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.58 per share
• Price / Book: 0.37

Miscellaneous

• Outstanding Shares: 52,981,000
• Free Float: 48,238,000
• Market Cap: $11.42 million
• Optionable: Not Optionable
• Beta: 0.51